Webpackaging logo

Aptar CSP Technologies’ Activ-Blister™ Solutions Now Available for Manufacturing in the EMEA Region

  • Aptar CSP Technologies
Europe, Health

Activ-Blister™ active packaging solutions deliver enhanced product stability and expedited speed-to-market for oral solid dose drugs in the EU

Aptar CSP Technologies, part of AptarGroup, Inc. and a leader in active material science solutions to ensure product protection, extend shelf life and improve patient experience, announces a new manufacturing site able to produce its Activ-Blister™ Solutions for oral slide dose drugs in Europe. The move is part of a key strategic effort to expand production of Activ-Blister™ technology globally and is the result of a 3-way collaboration between Aptar CSP, Uhlmann (a leading pharmaceutical packaging equipment manufacturer), and Ivers-Lee, www.iverslee.com, (a local contract manufacturing organization).

This collaboration consists of a fully automated Uhlmann blister machine validated to package oral solid dose drug products with Activ-Blister™ Solutions heat-staked to the foil at a rate of up to 250 blisters per minute (Figure 1). The equipment is designed to integrate Activ-Blister™ technology into the blister cavity with precision placement (Figure 2). The equipment has been fully-validated and is in place at Ivers-Lee, a CMO capable of manufacturing Activ-Blister™ solutions from R&D to commercialization. A CMO in EMEA will support regional customers and ensure speed-to-market.

“Expanding global manufacturing sites for Activ-Blister™ technology reflects our commitment to delivering global access to innovative active material science solutions for patients and consumers,” said Badre Hammond, VP Commercial Operations and GM APAC, Aptar CSP Technologies. “With manufacturing capabilities now available in in both the US and EMEA, we will turn our attention to bringing production of this technology to the Asia market.”

Activ-Blister™ Solutions integrates Aptar CSP’s proprietary 3-Phase Activ-Polymer™ platform technology into individual blister cavities to provide precision microclimate protection for sensitive drug products. This technology can be customized specifically for the drug developer’s formulation to provide a broad spectrum of specific drug protection including moisture adsorption, and oxygen and odor scavenging. The technology can also scavenge volatile organic compounds (VOCs) and emit aromas.

Representatives from Aptar CSP Technologies will be available at Pharmapack on May 18-19 in Paris, France to provide more information on this collaboration and the opportunities it presents. Visit Aptar at booth E46 or contact Francois Bidet at +33 6 2078 8153 or Francois.Bidet@Aptar.com to schedule a meeting.


Figure 1: Uhlmann Blister Machine Used to Manufacture Activ-Blister™ Solutions at Ivers-Lee
Figure 2: Activ-Blister™ technology remains attached to foil backing when blister is opened for enhanced patient safety

See also

Aptar CSP presents 'rethinking oral solid dose packaging' webinar

Aptar CSP Technologies – a leader in active packaging solutions that ensure product protection, enhance brand recognition and improve use experiences, and part of AptarGroup Inc – is presenting its Activ-Blister Solutions for the protection of moisture and oxygen-sensitive tablets and capsules, alongside FreeThink Technologies and its ASAPprime technology for accelerated shelf-life determination. The combination is a “right the first time” approach to stability challenges and blister package design that virtually eliminates protracted testing and costly reformulations.

CSP Technologies' focus for enhancing the shelf life for transdermal and oral solid dose drugs

Despite being two very different drug delivery platforms, oral solid doses and transdermal patches can face similar packaging headspace challenges that impact shelf life; besides moisture and oxygen ingress, exposure to certain conditions can lead to the formation of volatile organic compounds (VOCs) and other gases that, in turn, may interact with drug products and capsules, adversely impacting their stability.

  • Company News
  • English
  • Modified 17 May 2022
  • Hits 650